Literature DB >> 14990718

Characterization of functional hepatitis C virus envelope glycoproteins.

Anne Op De Beeck1, Cécile Voisset, Birke Bartosch, Yann Ciczora, Laurence Cocquerel, Zhenyong Keck, Steven Foung, François-Loïc Cosset, Jean Dubuisson.   

Abstract

Hepatitis C virus (HCV) encodes two envelope glycoproteins, E1 and E2, that assemble as a noncovalent heterodimer which is mainly retained in the endoplasmic reticulum. Because assembly into particles and secretion from the cell lead to structural changes in viral envelope proteins, characterization of the proteins associated with the virion is necessary in order to better understand how they mature to be functional in virus entry. There is currently no efficient and reliable cell culture system to amplify HCV, and the envelope glycoproteins associated with the virion have therefore not been characterized yet. Recently, infectious pseudotype particles that are assembled by displaying unmodified HCV envelope glycoproteins on retroviral core particles have been successfully generated. Because HCV pseudotype particles contain fully functional envelope glycoproteins, these envelope proteins, or at least a fraction of them, should be in a mature conformation similar to that on the native HCV particles. In this study, we used conformation-dependent monoclonal antibodies to characterize the envelope glycoproteins associated with HCV pseudotype particles. We showed that the functional unit is a noncovalent E1E2 heterodimer containing complex or hybrid type glycans. We did not observe any evidence of maturation by a cellular endoprotease during the transport of these envelope glycoproteins through the secretory pathway. These envelope glycoproteins were recognized by a panel of conformation-dependent monoclonal antibodies as well as by CD81, a molecule involved in HCV entry. The functional envelope glycoproteins associated with HCV pseudotype particles were also shown to be sensitive to low-pH treatment. Such conformational changes are likely necessary to initiate fusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990718      PMCID: PMC353750          DOI: 10.1128/jvi.78.6.2994-3002.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein.

Authors:  M Flint; J Dubuisson; C Maidens; R Harrop; G R Guile; P Borrow; J A McKeating
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization.

Authors:  A Op De Beeck; R Montserret; S Duvet; L Cocquerel; R Cacan; B Barberot; M Le Maire; F Penin; J Dubuisson
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

4.  Cell fusion activity of hepatitis C virus envelope proteins.

Authors:  S Takikawa; K Ishii; H Aizaki; T Suzuki; H Asakura; Y Matsuura; T Miyamura
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Characterization of aggregates of hepatitis C virus glycoproteins.

Authors:  Amélie Choukhi; André Pillez; Hervé Drobecq; Christian Sergheraert; Czeslaw Wychowski; Jean Dubuisson
Journal:  J Gen Virol       Date:  1999-12       Impact factor: 3.891

6.  Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein.

Authors:  M Flint; J M Thomas; C M Maidens; C Shotton; S Levy; W S Barclay; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein.

Authors:  J Dubuisson; S Duvet; J C Meunier; A Op De Beeck; R Cacan; C Wychowski; L Cocquerel
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

9.  Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins.

Authors:  L Cocquerel; C Wychowski; F Minner; F Penin; J Dubuisson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

10.  A model for the hepatitis C virus envelope glycoprotein E2.

Authors:  A T Yagnik; A Lahm; A Meola; R M Roccasecca; B B Ercole; A Nicosia; A Tramontano
Journal:  Proteins       Date:  2000-08-15
View more
  99 in total

1.  Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay.

Authors:  Mariko Kobayashi; Michael C Bennett; Theodore Bercot; Ila R Singh
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 3.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

4.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

Review 5.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

6.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

7.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

9.  Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication.

Authors:  Lucie Goueslain; Khaled Alsaleh; Pauline Horellou; Philippe Roingeard; Véronique Descamps; Gilles Duverlie; Yann Ciczora; Czeslaw Wychowski; Jean Dubuisson; Yves Rouillé
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 10.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.